W. M. Stadler, “Effective Therapy for Metastatic Renal Cancer, Whither to Now,” Journal of Clinical Oncology, Vol. 27, No. 22, 2009, pp. 3573-3574.
doi:10.1200/JCO.2009.22.5250
-
TITLE:
Tumor Resistance to Molecularly Targeted Agents
AUTHORS:
James Chen, Peter S. Edelstein, Philip J. Johnson, Robert Lustig, Lucien Ooi
KEYWORDS:
Tumor Resistance, Signaling Pathway, Gene Pathway, Oncogene, Renal Cell Carcinoma
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.2 No.2,
July
8,
2011
ABSTRACT: Despite the development of new targeted cancer therapies, primary and secondary tumors continue to be a leading cause of suffering and mortality worldwide. The complexity and heterogeneity of malignancies ultimately result in tumor resistance to therapies, such as EGFR inhibitiors, anti-angiogenesis agents, and tyrosine kinase inhibitors. An example of targeted therapies for renal cell carcinoma is presented, including the SAE profile and efficacy of 6 targeted agents. Although survival is improved, resistance and an increased side effect profile diminish the benefits of these agents. New agents are needed which are pathway independent and which can overcome tumor resistance without adding to the side effect profile of current therapies.
Related Articles:
Clinical Predictors of Cetuximab for First-Line Therapy of Metastatic Colorectal Cancer: A Single Institutional Retrospective Study
Yuki Morishita, Hiroaki Tanioka, Motoi Asano, Kotomi Tokuyama, Hiroko Okamoto, Tomohisa Okamoto, Takako Oda, Masatoshi Ohta, Masayuki Fukuzawa
DOI:
10.4236/jct.2017.89072
640 Downloads 1,191 Views Citations
Pub. Date:
September
12,
2017
Evaluation of Targeted Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma in Tunisia
Khaled Ben Ahmed, Amira Daldoul, Ghassen Tlili, Laila Ben Fatma, Olfa Gharbi, Mahdi Afrit, Jihene Fkih, Hammouda Boussen, Mounir Frikha, Faouzi Mosbah, Slim Ben Ahmed
DOI:
10.4236/ojgas.2016.67025
1,414 Downloads 2,262 Views Citations
Pub. Date:
July
27,
2016
